Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cingulate Inc.

Get SEC filing alerts via email and in your feed for Cingulate Inc.

CING CINGW

Cingulate Inc.

About Cingulate Inc.

Cingulate Inc. is a biopharmaceutical company developing innovative drugs using its proprietary Precision Timed Release platform to improve treatment of conditions like ADHD and anxiety. Its pipeline includes next-generation stimulant medications and non-stimulant therapies designed for once-daily dosing, faster onset, and better tolerability. The company focuses on clinical development, strategic partnerships, licensing, and leveraging its intellectual property to address unmet medical needs in large markets.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cingulate Inc.

1
1
Cingulate Inc. Cingulate Inc. Reports $9.3 Million Net Loss and $30.9 Million in Total Assets for Quarter Ending March 31, 2026

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Cingulate Inc. Cingulate Inc. Reports $22.4 Million Net Loss for Fiscal Year 2025 Amid Rising Expenses

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Cingulate Inc. Cingulate Inc. Reports $7.34 Million Net Loss and Financial Challenges in Latest Quarter

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cingulate Inc. Cingulate Inc. Reports $4.8 Million Net Loss in Q2 2025, Submits NDA for CTx-1301

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cingulate Inc. Cingulate Inc. Reports $3.8 Million Net Loss in Q1 2025, Increases R&D and G&A Expenses

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cingulate Inc. Cingulate Inc. Reports $15.5 Million Net Loss for Fiscal Year 2024, Down from $23.5 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cingulate Inc. Cingulate Inc. Reports Improved Financials, Reduced Losses in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments